EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Myeloma bone disease: A constant problem in the changing landscape of myeloma management

D Swan iD, A Yong, K Vandyke, J Hocking

British Journal of Haematology · 2026-02 · 208 (2) · 399-412

DOI: 10.1111/bjh.70240 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 03.11.2025. Verfasst von D Swan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Austin Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Bone Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 110 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes for patients with multiple myeloma have improved markedly in recent years due to the introduction of highly effective immune‐mediated anti‐myeloma therapies in both newly diagnosed and relapsed patients. Conversely, while patients are living longer, myeloma bone disease continues to contribute significantly to morbidity and mortality. Routine incorporation of anti‐resorptive therapies into patient management is recommended by consensus guidelines; however, patients continue to sustain skeletal‐related events, including pathological fractures. In this review, we discuss the diagnosis and pathogenesis of myeloma bone disease and the evidence underpinning guideline recommendations for the use of bisphosphonates in patients with myeloma. We consider novel approaches to reducing bone disease presented by targeting osteoblastic activity, the impact of anti‐myeloma therapies themselves on bone disease and the role of biomarkers to monitor disease activity and guide the intensity and duration of bone‐targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBone DiseasesHumansBone Density Conservation AgentsDiphosphonatesDisease Management

Stichwörter der Autor:innen

biomarkerbisphosphonatemyelomaosteolytic

Substanzen

Bone Density Conservation AgentsDiphosphonates

Autor:innen und Institutionen

  • Department of Haematology, Austin Health, Melbourne, Victoria, Australia.
  • Department of Haematology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
  • Myeloma Research Laboratory, Faculty of Health and Medical Sciences, School of Biomedicine, University of Adelaide, Adelaide, South Australia, Australia.
  • Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

ORCID-Profile: D Swan

Zitieren

APA

Swan, D., Yong, A., Vandyke, K., & Hocking, J. (2026). Myeloma bone disease: A constant problem in the changing landscape of myeloma management. British Journal of Haematology, 208(2), 399-412. https://doi.org/10.1111/bjh.70240

Vancouver

Swan D, Yong A, Vandyke K, Hocking J. Myeloma bone disease: A constant problem in the changing landscape of myeloma management. British Journal of Haematology. 2026;208(2):399-412. doi:10.1111/bjh.70240

BibTeX
@article{Swan2026,
  author = {Swan, D and Yong, A and Vandyke, K and Hocking, J},
  title = {Myeloma bone disease: A constant problem in the changing landscape of myeloma management},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {2},
  pages = {399--412},
  doi = {10.1111/bjh.70240}
}
Kostenlos starten →